Why the study?
Does fixed-dose subcutaneous low-molecular-weight heparin reduce new episodes of venous thromboembolism compared to adjusted-dose intravenous heparin in patients with proximal vein thrombosis?
Does fixed-dose subcutaneous low-molecular-weight heparin reduce new episodes of venous thromboembolism compared to adjusted-dose intravenous heparin in patients with proximal vein thrombosis?
Once-daily subcutaneous low-molecular-weight heparin is at least as effective as continuous intravenous heparin for proximal deep vein thrombosis, with significant reductions in initial major bleeding and overall mortality.
Answers are grounded in this paper and cite their sources.
Supports LMWH as at least as effective as IV heparin for proximal DVT; extends options for convenient outpatient regimens in practice and trials.
Low-molecular-weight heparin, compared with unfractionated heparin, has a higher bioavailability and a more prolonged half-life. There are limited data comparing the use of low-molecular-weight heparin with unfractionated heparin for the treatment of deep vein thrombosis. We have compared fixed-dose, subcutaneous low-molecular-weight heparin given once daily with adjusted-dose intravenous heparin given by continuous infusion in a multicenter double-blind clinical trial for the initial treatment of patients with proximal vein thrombosis. Clinical outcomes were objectively documented. Six of 213 patients receiving low-molecular-weight heparin (2.8%) and 15 of 219 patients receiving intravenous heparin (6.9%) developed new episodes of venous thromboembolism (p = 0.07; 95% confidence interval for the difference, 0.02%-8.1%). During initial therapy, major bleeding occurred in one patient receiving low-molecular-weight heparin (0.5%) and in 11 patients receiving intravenous heparin (5.0%), a risk reduction of 91% (p = 0.006). This apparent protection against major bleeding was lost during long-term therapy. Minor bleeding complications were rare. During the period of the study, 10 patients receiving low-molecular-weight heparin (4.7%) died, as compared with 21 patients receiving intravenous heparin (9.6%), a risk reduction of 51%(p = 0.049). This study shows that low-molecular-weight heparin is at least as effective as classic intravenous heparin therapy and that there was a reduction in deaths and bleeding complications. Furthermore, low-molecular-weight heparin was more convenient to administer. The simplified therapy with low-molecular-weight heparin given by once-daily subcutaneous injection without monitoring may allow patients with uncomplicated proximal deep vein thrombosis to be cared for as outpatients.
No takes yet. Share an insight, caveat, or question.
Hull et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: